Short Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Expands By 119.0%

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 64,600 shares, a growth of 119.0% from the May 15th total of 29,500 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 643,400 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating in a research note on Friday, June 6th.

Daiichi Sankyo Stock Performance

DSNKY traded down $0.39 on Monday, hitting $24.21. 141,674 shares of the stock traded hands, compared to its average volume of 263,462. Daiichi Sankyo has a 52 week low of $20.92 and a 52 week high of $42.48. The firm has a market capitalization of $45.87 billion and a PE ratio of 28.15. The business has a fifty day moving average price of $24.62 and a two-hundred day moving average price of $25.58. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $0.30 earnings per share for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. The company had revenue of $3.40 billion for the quarter. On average, research analysts predict that Daiichi Sankyo will post 0.73 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.